Pharmaceutical Executive Daily: Inizio Engage launches Connected Insights

Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences industry.

In today's Pharmaceutical Executive Daily, Johnson & Johnson, Processa Pharmaceuticals, and Relation strike new deals spanning cell therapy, BTK inhibition, and AI-driven target discovery, Inizio Engage launches Connected Insights to turn medical information interactions into strategic intelligence, and a commentary argues pharma companies need to manage direct-to-patient sales as a core commercial channel rather than a side program.

Johnson & Johnson has entered strategic agreements with Sail Biomedicines, committing $785 million in initial payments, including a $465 million equity stake, plus up to $140 million in milestone payments, alongside an exclusive option to acquire the company outright for $2.58 billion. Sail's in vivo CAR-T platform is designed to reprogram a patient's immune cells directly inside the body, aiming to reset the immune system without the manufacturing constraints of traditional cell therapies. Separately, Processa Pharmaceuticals acquired Vidya Therapeutics and its BTK inhibitor VT-7208, alongside a roughly $200 million private placement to fund trials in food allergy, chronic spontaneous urticaria, and relapsing multiple sclerosis. And Relation entered a research collaboration with GSK worth up to $110 million to generate large-scale cellular data for target discovery using Relation's MORGAN foundation model.

Inizio Engage has launched Connected Insights, an expansion of its Global Medical Information platform designed to convert the more than one million scientific interactions it handles annually into strategic intelligence for pharmaceutical clients. The offering combines expanded Asia-Pacific capabilities with AI-enabled tools including training personas, speech analytics, and virtual agents, and the company reports a tenfold increase in AI-powered training simulations alongside a 50 percent improvement in training success. The goal is to help Medical Affairs teams move beyond simply answering inquiries toward identifying trends and unmet needs across a product's full lifecycle.

Finally, a new commentary argues that direct-to-patient sales have moved from a goodwill gesture to a commercial necessity, pointing out that nine major pharmaceutical companies now sell branded drugs directly to patients at discounts of 55 to 80 percent off list price. The piece credits this shift to IRA drug price negotiation taking effect this year and to PBMs extracting 45 to 55 percent of list price before manufacturers see net revenue.

Thanks for listening to Pharmaceutical Executive Daily. For more updates and in-depth analysis, visit PharmExec.com.